<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02730338</url>
  </required_header>
  <id_info>
    <org_study_id>GAP4</org_study_id>
    <nct_id>NCT02730338</nct_id>
  </id_info>
  <brief_title>INTense ExeRcise for surviVAL Among Men With Metastatic Prostate Cancer (INTERVAL - GAP4)</brief_title>
  <acronym>INTERVAL</acronym>
  <official_title>INTense ExeRcise for surviVAL Among Men With Metastatic Prostate Cancer (INTERVAL - GAP4): A Multicentre, Randomised, Controlled, Phase III Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Movember Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Edith Cowan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Epworth Healthcare</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Movember Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if supervised high intensity aerobic and resistance training increases overall&#xD;
      survival compared to self-directed exercise in patients with metastatic prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Overall survival will be measured from the time of randomization until death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Progression</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Time to disease progression will be measured from randomization until the first of the following: first CT or bone scan documenting disease progression, initiation of a new therapy for mPC (clinical progression), or first occurrence of a Symptomatic Skeletal Related Event (SSE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic Skeletal Related Events (SSE)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Time to first occurrence of SSE will be defined as the time from randomization to documentation of any of the following (whichever occurs first) + 1 day:&#xD;
Use of external beam radiation therapy to relieve bone pain&#xD;
Occurrence of new symptomatic pathological bone fractures that may be vertebral or non-vertebral. Asymptomatic compression fractures detected by radiology review only will not be considered a SSE.&#xD;
Spinal cord compression&#xD;
Change in antineoplastic therapy to treat bone pain&#xD;
Surgical intervention to treat bone pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opiate Use</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Opiate use will be assessed via BPI-SF, the medical record review at entry with a lead-in period (&lt;28 days). The questionnaires will be administered every three cycles until month 24, and in month 36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic Use</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Analgesic use will be assessed via BPI-SF, the World Health Organisation (WHO) analgesic scale, and medical record review at entry with a lead-in period (&lt;28 days). The WHO analgesic scale will be completed every three cycles (based on medical review) and questionnaires will be administered every three cycles until month 24, and in month 36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker analysis</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Inflammatory and cytokine systemic milieu</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker analysis</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Insulin/Glucose Metabolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker analysis</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Androgen biosynthesis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Physical and emotional quality of life measured by the questionnaires- Functional Assessment of Cancer Therapy- Prostate (FACT-P), Functional assessment of Chronic Illness Therapy (FACIT-Fatigue), and EuroQOL Five Dimension Questionnaire (EQ5D) will be assessed every 3 cycles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Function</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Physical function will be assessed using strength assessments (1RM), a cardiopulmonary exercise test (CPET) and a functional performance test (400m walk)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Pain will be assessed via questionnaire Brief Pain Inventory- short form (BPI-SF) and medical record review at entry with a lead-in period (&lt;28 days) and repeated measures will occur every three cycles</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">866</enrollment>
  <condition>Metastatic Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: Supervised exercise group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Supervised high intensity aerobic and resistance exercise tapering to self management with psychosocial support</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Self directed exercise group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Self directed exercise and psychosocial support group</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>High intensity aerobic and resistance training</intervention_name>
    <arm_group_label>Arm A: Supervised exercise group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Psychosocial support</intervention_name>
    <arm_group_label>Arm A: Supervised exercise group</arm_group_label>
    <arm_group_label>Arm B: Self directed exercise group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        mCRPC status:&#xD;
&#xD;
          -  mCRPC patients defined as; adenocarcinoma of the prostate with systemic metastatic&#xD;
             disease despite castrate levels of testosterone (&lt;50 ng/dL) due to orchiectomy or LHRH&#xD;
             agonist.&#xD;
&#xD;
             o Patients must have one or more of the following to be considered mCRPC&#xD;
&#xD;
          -  Metastatic Disease Progression: &gt;20% increase in the sum of diameters of measurable&#xD;
             lesions from the time of maximal regression or appearance of one or more new lesions.&#xD;
&#xD;
          -  Bone Scan Progression: Appearance of one or more new lesions on bone scan attributable&#xD;
             to prostate cancer.&#xD;
&#xD;
          -  PSA Progression: PSA ≥2 ng/ml that has risen serially on at least two occasions, each&#xD;
             at least one week apart (PSA1 &lt; PSA2 &lt; PSA3).&#xD;
&#xD;
          -  PSMA PET/CT scan progression: Appearance of one or more new lesions on PSMA PET/CT&#xD;
             scan attributable to prostate cancer.&#xD;
&#xD;
          -  At enrolment, mCRPC patients must fit into one of the following 5 categories:&#xD;
&#xD;
               1. Treatment naïve for mCRPC (have not yet started approved therapies for CRPC ie:&#xD;
                  Abiraterone/Enzalutamide/Apalutamide / or Docetaxel, Cabazitaxel or other&#xD;
                  approved first line chemotherapy; less than 4 weeks on approved therapies is&#xD;
                  still considered to be treatment naïve) Or&#xD;
&#xD;
               2. Receiving Abi/Enza/Apa for mCRPC AND responding or stable (PSA values must be&#xD;
                  stable or declining after at least 4 weeks since starting Abi/Enza/Apa for mCRPC)&#xD;
                  Or&#xD;
&#xD;
               3. Patients with PSA progression while on Abi/Enza/Apa are eligible as long as they&#xD;
                  are asymptomatic AND there is no intent on starting chemotherapy within 6 months&#xD;
                  Or&#xD;
&#xD;
               4. Patients treated with Docetaxel, Cabazitaxel or other approved first line&#xD;
                  chemotherapy as first line for mCRPC who are asymptomatic without ANY evidence of&#xD;
                  progression Or&#xD;
&#xD;
               5. Patients may have progressed following first line Docetaxel, Cabazitaxel or other&#xD;
                  first line chemotherapy and are now receiving treatment with Abi/Enza/Apa. These&#xD;
                  patients must absolutely be responding or stable (PSA values must be stable or&#xD;
                  declining after starting Abi/Enza/Apa treatment) and have an estimated life&#xD;
                  expectancy of more than 1 year.&#xD;
&#xD;
                  mHSPC Status:&#xD;
&#xD;
          -  mHSPC patients must be classified as either high-risk or high-volume mHSPC. These&#xD;
             groups are defined as adenocarcinoma of the prostate with systemic metastatic disease&#xD;
             and patients also fit into one of the following 2 categories: 6. High-risk: defined as&#xD;
             having at least 2 of three criteria: (i) Gleason score ≥8, (ii) presence of ≥3 lesions&#xD;
             on bone scan, or (iii) presence of INTERVAL Protocol Version 5.0, 19 August 2019 4&#xD;
             measurable visceral lesions (PSMA PET imaging should not be used in the definition of&#xD;
             high-risk disease) Or 7. High-volume: defined as having the presence of visceral&#xD;
             metastases and/or ≥ four bone metastases with at least one outside of the vertebral&#xD;
             column and pelvis (PSMA PET imaging should not be used in the definition of&#xD;
             high-volume disease)&#xD;
&#xD;
        Additional criteria for all groups:&#xD;
&#xD;
          -  All patients will be required to be on ADT during the study period or have had a prior&#xD;
             bilateral orchiectomy.&#xD;
&#xD;
          -  Men with small cell neuroendocrine tumours or features of small cell disease are not&#xD;
             eligible.&#xD;
&#xD;
          -  ≥4 weeks since last major surgery and fully recovered.&#xD;
&#xD;
          -  No known contraindications to high intensity exercise, including, but not limited to:&#xD;
             brain metastases; current congestive heart failure (New York Heart Association Class&#xD;
             II, III or IV); serious or non-healing wound, ulcer, or bone fracture; spinal cord&#xD;
             compromise or instrumentation due to metastatic disease; peripheral neuropathy ≥grade&#xD;
             3. No serious cardiovascular events within 12 months including, but not limited to,&#xD;
             transient ischemic attack (TIA), cerebrovascular accident (CVA), or myocardial&#xD;
             infarction (MI). Patients with a history of hypertension must be well-controlled (&lt;&#xD;
             160/90) on anti-hypertensive therapy.&#xD;
&#xD;
          -  Halabi Nomogram score &lt;1951 (Risk Category rated as low or intermediate risk)&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Required Baseline Laboratory Values: ANC ≥ 1500/uL; Platelet count ≥ 100,000/uL;&#xD;
             Creatinine ≤ 1.5 x upper limits of normal; Bilirubin ≤ 1.5 x upper limits of normal;&#xD;
             AST ≤ 1.5 x upper limits of normal; Serum testosterone ≤ 50 ng/dL&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Medical clearance by treating physician to undergo a symptom-limited cardiopulmonary&#xD;
             exercise test and vigorous aerobic and resistance exercise training, and able to&#xD;
             complete an acceptable cardiopulmonary exercise test.&#xD;
&#xD;
          -  Exercise Coordination Centre (ECC) review and approval of subject's screening bone&#xD;
             scan / areas with bone metastases.&#xD;
&#xD;
          -  Men participating in vigorous aerobic exercise for &gt;60 min/week or structured&#xD;
             resistance exercise ≥2 days/week, are not eligible.&#xD;
&#xD;
          -  Subject is willing and able to use technological aspects of the trial.&#xD;
&#xD;
          -  The subject is fluent in the language as designated by the institution at which he&#xD;
             would be enrolled.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Newton</last_name>
    <role>Study Chair</role>
    <affiliation>Edith Cowan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fred Saad</last_name>
    <role>Study Chair</role>
    <affiliation>Centre hospitalier de l'Université de Montréal (CHUM)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anthony Treacy</last_name>
    <phone>+61 (0)412872510</phone>
    <email>anthony.treacy@movember.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennette Sison</last_name>
    <phone>+01 415 885 3692</phone>
    <email>Jennette.Sison@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars Sinai Medical Centre</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennette Sison</last_name>
      <phone>415-885-3692</phone>
      <email>Jennette.Sison@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>June Chan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Kessler</last_name>
      <email>ELIZABETH.KESSLER@UCDENVER.EDU</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Kessler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Ryan</last_name>
      <email>ryanc@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Charles Ryan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerri Winters-Stone</last_name>
      <email>wintersk@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Centre</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Plymate</last_name>
    </contact>
    <investigator>
      <last_name>Jonathan Wright</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Canberra</name>
      <address>
        <city>Canberra</city>
        <state>Australian Capital Territory</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kellie Toohey</last_name>
      <email>Kellie.Toohey@canberra.edu.au</email>
    </contact>
    <investigator>
      <last_name>Kellie Toohey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Lisa Horvath</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Australian Prostate Cncr Research Centre</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Nelson</last_name>
      <email>colleen.nelson@qut.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GenesisCare Wesley</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vicki Sproule</last_name>
      <email>Vicki.Sproule@genesiscare.com</email>
    </contact>
    <investigator>
      <last_name>James MacKean</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Queensland</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Skinner</last_name>
      <email>t.skinner@uq.edu.au</email>
    </contact>
    <investigator>
      <last_name>Tina Skinner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Epworth Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Layton</last_name>
      <email>Gary.Layton@epworth.org.au</email>
    </contact>
    <investigator>
      <last_name>Mark Frydenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Victoria University / Sunshine Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Hayes</last_name>
      <email>alan.hayes@vu.edu.au</email>
    </contact>
    <investigator>
      <last_name>Shirley Wong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Edith Cowan University</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Newton</last_name>
      <email>r.newton@ecu.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerry Courneya</last_name>
      <email>kerry.courneya@ualberta.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>QEII Cancer Centre / Dalhousie University</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Scott Grandy</last_name>
      <email>Scott.Grandy@Dal.Ca</email>
    </contact>
    <investigator>
      <last_name>Scott Grandy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal (CRCHUM)</name>
      <address>
        <city>Montreal</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fred Saad</last_name>
      <email>fred.saad@umontreal.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junru Chen</last_name>
      <email>827018614@qq.com</email>
    </contact>
    <investigator>
      <last_name>Sulin Cheng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>German Sport University Cologne</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wilhelm Bolch</last_name>
      <email>w.bloch@dshs-koeln.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Trinity University</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephen Finn</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emiel Sneekes</last_name>
      <email>e.sneekes@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Hans Bussmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Surrey</name>
      <address>
        <city>Guildford</city>
        <state>Surrey</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph Manders</last_name>
      <email>r.manders@surrey.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Ralph Manders</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen's University Belfast</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gillian Prue</last_name>
      <email>g.prue@qub.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Suneil Jain</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Glasgow</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hing Leung</last_name>
      <email>h.leung@beatson.gla.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Hing Leung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kings College London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mieke Van Hemelrijck</last_name>
      <email>mieke.vanhemelrijck@kcl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Sarah Rudman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>China</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 10, 2016</study_first_submitted>
  <study_first_submitted_qc>March 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2016</study_first_posted>
  <last_update_submitted>August 24, 2020</last_update_submitted>
  <last_update_submitted_qc>August 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Castrate resistant</keyword>
  <keyword>Exercise</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Prostate cancer</keyword>
  <keyword>Hormone sensitive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

